Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd. has applied for quotation of 413,793 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 27 February 2026. The additional securities, linked to a previously announced transaction, will modestly expand the company’s share base and may provide incremental capital or support for its ongoing corporate and operational activities, while slightly diluting existing shareholders.
The move underscores Rhythm Biosciences’ continued use of equity markets to support its business objectives and maintain its listing compliance. For investors and other stakeholders, the quotation of these new shares reflects routine capital management and may signal ongoing funding or strategic initiatives aligned with the company’s bioscience development plans.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. is an ASX-listed biotechnology company operating under the ticker RHY. The company is engaged in developing and commercializing bioscience technologies, with its shares traded as ordinary fully paid securities on the Australian Securities Exchange, giving investors access to its growth in the life sciences sector.
Average Trading Volume: 993,151
Technical Sentiment Signal: Buy
Current Market Cap: A$69.21M
See more insights into RHY stock on TipRanks’ Stock Analysis page.